PET/CT Imaging Characteristics After Radioembolization of Hepatic Metastasis from Breast Cancer
- 1 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in CardioVascular and Interventional Radiology
- Vol. 43 (3), 488-494
- https://doi.org/10.1007/s00270-019-02375-7
Abstract
Purpose To define positron emission tomography/computed tomography (PET/CT) imaging characteristics during follow-up of patients with metastatic breast cancer (MBC) treated with yttrium-90 (Y90) radioembolization (RE). Materials and Methods From January 2011 to October 2017, 30 MBC patients underwent 38 Y90 glass or resin RE treatments. Pre-RE PET/CT was performed on average 51 days before RE. There were 68 PET/CTs performed after treatment. Response was assessed using modified PERCIST criteria focusing on the hepatic territory treated with RE, normalizing SUVpeak to the mean SUV of liver uninvolved by tumor. An objective response (OR) was defined as a decrease in SUVpeak by at least 30%. Results Of the 68 post-RE scans, 6 were performed at 0-30 days, 15 at 31-60 days, 9 at 61-90 days, 13 at 91-120 days, 14 scans at 121-180 days, and 11 scans at > 180 days after RE. Of the 30 patients, 25 (83%) achieved OR on at least one follow-up. Median survival was 15 months after the first RE administration. Highest response rates occurred at 30-90 days, with over 75% of cases demonstrating OR at that time. After 180 days, OR was seen in only 25%. There was a median TTP of 169 days among responders. Conclusion In MBC, follow-up PET/CT after RE demonstrates optimal response rates at 30-90 days, with progression noted after 180 days. These results help to guide the timing of imaging and also to inform patients of expected outcomes after RE.Funding Information
- NIH/NCI Cancer Center Support Grant (P30 CA008748)
- Breast Cancer Research Foundation
This publication has 33 references indexed in Scilit:
- The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE).European Journal of Nuclear Medicine and Molecular Imaging, 2014
- Yttrium-90 Radioembolization for Unresectable, Chemoresistant Breast Cancer Liver Metastases: A Large Single-Center Experience of 40 PatientsAnnals of Surgical Oncology, 2013
- Response Criteria in Oncologic Imaging: Review of Traditional and New CriteriaRadioGraphics, 2013
- Validation of Several SUV-Based Parameters Derived from 18F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal CancerJournal of Nuclear Medicine, 2013
- Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenibHepatology, 2013
- Prognostic Value of 18F-Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography in Predicting Survival in Patients with Unresectable Metastatic Melanoma to the Liver Undergoing Yttrium-90 RadioembolizationJournal of Vascular and Interventional Radiology, 2012
- 18F-FDG PET/CT Predicts Survival After Radioembolization of Hepatic Metastases from Breast CancerJournal of Nuclear Medicine, 2012
- Tumor Response after Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Comparison of Diffusion-weighted Functional MR Imaging with Anatomic MR ImagingJournal of Vascular and Interventional Radiology, 2008
- Yttrium-90 Radioembolization of Hepatocellular Carcinoma and Metastatic Disease to the LiverSeminars in Interventional Radiology, 2006
- Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign VariantsRadioGraphics, 1999